This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Shanghai Haoyuan Medchemexpress Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Zhi Guo Zhou: Innovator in Pharmaceutical Chemistry
Introduction
Zhi Guo Zhou is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of camptothecin derivatives. His innovative work has the potential to impact cancer treatment and drug development.
Latest Patents
Zhi Guo Zhou holds a patent for an "Intermediate for synthesizing camptothecin derivative, preparation method therefor, and use thereof." This patent describes an intermediate compound A that can be synthesized from 3-fluoro-4-methylaniline through acylation, bromination, and cross-coupling reactions. The intermediate A is crucial for preparing intermediate B, which is further used to produce exatecan mesylate. The process is characterized by low-cost starting materials, moderate reaction conditions, simple operations, and high yields, making it suitable for industrial production.
Career Highlights
Zhi Guo Zhou is associated with Shanghai Haoyuan Medchemexpress Co., Ltd., where he applies his expertise in medicinal chemistry. His work focuses on developing efficient methods for synthesizing pharmaceutical compounds, contributing to advancements in drug formulation and production.
Collaborations
Zhi Guo Zhou collaborates with notable colleagues, including Tao Ma and Kui Mei. Their combined efforts enhance the research and development capabilities within their organization, fostering innovation in the pharmaceutical sector.
Conclusion
Zhi Guo Zhou's contributions to pharmaceutical chemistry, particularly through his patent on camptothecin derivatives, highlight his role as an innovator in the field. His work not only advances scientific knowledge but also holds promise for improving cancer treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile